Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Prognostic impact of HER2-low expression in hormone receptor positive early breast cancer

Background: Recent data suggest that human epidermal growth factor receptor 2 (HER2)-low breast cancer may represent a distinct entity. We aimed to compare disease characteristics and outcomes between HER2-low and HER2-0 in estrogen receptor (ER) positive, early-stage breast cancer. Methods: A singl...

Full description

Bibliographic Details
Main Authors:	Raz Mutai, Tamar Barkan, Assaf Moore, Michal Sarfaty, Tzippy Shochat, Rinat Yerushalmi, Salomon M. Stemmer, Hadar Goldvaser
Format:	Article
Language:	English
Published:	Elsevier 2021-12-01
Series:	Breast
Subjects:	Breast cancer HER2-Low Oncotype DX RS Genomic risk Prognosis
Online Access:	http://www.sciencedirect.com/science/article/pii/S0960977621004367

Similar Items

The concordance of treatment decision guided by OncotypeDX and the PREDICT tool in real‐world early‐stage breast cancer
by: Daniel A. Goldstein, et al.
Published: (2020-07-01)

Patient and physician factors associated with Oncotype DX and adjuvant chemotherapy utilization for breast cancer patients in New Hampshire, 2010–2016
by: Thomas M. Schwedhelm, et al.
Published: (2020-09-01)

How Canadian Oncologists Use Oncotype DX for Treatment of Breast Cancer Patients
by: Xiaofu Zhu, et al.
Published: (2021-02-01)

Impact of Oncotype DX testing on ER+ breast cancer treatment and survival in the first decade of use
by: Evelien Schaafsma, et al.
Published: (2021-07-01)

Does Mode of Surgical Intervention Based on Oncotype DX Score Influence Disease Recurrence in Early Breast Cancer?
by: T. M. Aherne, et al.
Published: (2020-04-01)

The Distribution and Outcomes of the 21-Gene Recurrence Score in T1-T2N0 Estrogen Receptor-Positive Breast Cancer With Different Histologic Subtypes
by: Jun Wang, et al.
Published: (2018-12-01)

Spotlight on the utility of the Oncotype DX® breast cancer assay
by: Siow ZR, et al.
Published: (2018-02-01)

Quantitative nuclear histomorphometric features are predictive of Oncotype DX risk categories in ductal carcinoma in situ: preliminary findings
by: Haojia Li, et al.
Published: (2019-10-01)

Practical consensus recommendations on management of HR + ve early breast cancer with specific reference to genomic profiling
by: S Aggarwal, et al.
Published: (2018-01-01)

Chemotherapy and 21-gene recurrence score testing for older breast cancer patients: A competing-risks analysis
by: Ping Zhou, et al.
Published: (2020-12-01)

Risk stratification of ER‐positive breast cancer patients: A multi‐institutional validation and outcome study of the Rochester Modified Magee algorithm (RoMMa) and prediction of an Oncotype DX® recurrence score <26
by: Bradley M. Turner, et al.
Published: (2019-08-01)

Oncotype DX Breast Recurrence Score Distribution and Chemotherapy Benefit Among Women of Different Age Groups With HR-Positive, HER2-Negative, Node-Negative Breast Cancer in the SEER Database
by: Ran Cheng, et al.
Published: (2020-10-01)

Levels of uPA and PAI-1 in breast cancer and its correlation to Ki67-index and results of a 21-multigene-array
by: Hans-Ullrich Völker, et al.
Published: (2018-08-01)

Implications of the 21-gene recurrence score assay (Oncotype DX) on adjuvant treatment decisions in ER-positive early-stage breast cancer patients: experience of Kuwait Cancer Control Center
by: Salah Fayaz, et al.
Published: (2020-03-01)

The impact of tumor detection method on genomic and clinical risk and chemotherapy recommendation in early hormone receptor positive breast cancer
by: Yael Bar, et al.
Published: (2021-12-01)

Comparison of GenesWell BCT Score With Oncotype DX Recurrence Score for Risk Classification in Asian Women With Hormone Receptor-Positive, HER2-Negative Early Breast Cancer
by: Mi Jeong Kwon, et al.
Published: (2019-07-01)

Clinical use of the Oncotype DX genomic test to guide treatment decisions for patients with invasive breast cancer
by: McVeigh TP, et al.
Published: (2017-05-01)

The ZNF217 Biomarker Predicts Low- and High-Risk Oncotype DX® Recurrence Score in ER-Positive Invasive Breast Cancers
by: Pascale A. Cohen, et al.
Published: (2019-05-01)

Pleomorphic adenoma of the breast: A potential morphologic and molecular pitfall in the era of genomic risk stratification
by: Margaret Moore, et al.
Published: (2021-03-01)

Adjuvant treatment recommendations for patients with ER-positive/HER2-negative early breast cancer by Swiss tumor boards using the 21-gene recurrence score (SAKK 26/10)
by: Bernhard C. Pestalozzi, et al.
Published: (2017-04-01)

Clinical Utility of Gene Expression Profiling Data for Clinical Decision-Making Regarding Adjuvant Therapy in Early Stage, Node-Negative Breast Cancer: A Case Report
by: Steven R. Schuster, et al.
Published: (2012-09-01)

Corrigendum: Genomic Assays in Node Positive Breast Cancer Patients: A Review
by: Maroun Bou Zerdan, et al.
Published: (2021-04-01)

Genomic Assays in Node Positive Breast Cancer Patients: A Review
by: Maroun Bou Zerdan, et al.
Published: (2021-02-01)

The impact of endogenous estrogen exposures on the characteristics and outcomes of estrogen receptor positive, early breast cancer
by: Yasmin Korzets, et al.
Published: (2021-08-01)

Invasive Ductal Breast Cancer with Osteoclast-Like Giant Cells: A Case Report Based on the Gene Expression Profile for Changes in Management
by: Azzurra Irelli, et al.
Published: (2021-02-01)

Prospective observational study on the impact of the 21-gene assay on treatment decisions and resources optimization in breast cancer patients in Lombardy: The BONDX study
by: Alberto Zambelli, et al.
Published: (2020-08-01)

Personalized treatment of women with early breast cancer: a risk-group specific cost-effectiveness analysis of adjuvant chemotherapy accounting for companion prognostic tests OncotypeDX and Adjuvant!Online
by: Beate Jahn, et al.
Published: (2017-10-01)

Genomic testing in international guidelines
by: Peter Kern, et al.
Published: (2013-10-01)

Significance of Oncotype DX 21-Gene Test and Expression of Long Non-Coding RNA MALAT1 in Early and Estrogen Receptor-Positive Breast Cancer Patients
by: Huang Z, et al.
Published: (2021-01-01)

Oncotype DX Test Receipt among Latina/Hispanic Women with Early Invasive Breast Cancer in New Jersey: A Registry-Based Study
by: Nicholas Acuna, et al.
Published: (2021-05-01)

Communicating Results of New Genomic Tests to Physicians
by: JIN, JING
Published: (2009)

Locoregional therapy in de novo metastatic breast cancer: Systemic review and meta-analysis
by: Daniel Reinhorn, et al.
Published: (2021-08-01)

Anti-HER2/neu Antibody Reduces Chemotherapy-Induced Ovarian Toxicity—From Bench to Bedside
by: Mattan Levi, et al.
Published: (2020-12-01)

Characterizing Metastatic HER2-Positive Gastric Cancer at the CDH1 Haplotype
by: Laura Caggiari, et al.
Published: (2017-12-01)

Prognostic value of HER3, PTEN and p-HER2 expression in patients with HER2positive breast cancer
by: Sylwia Dębska-Szmich, et al.
Published: (2015-05-01)

Should women with early breast cancer under 40 years of age have a routine 21-gene recurrence score testing: A SEER database study
by: Kai-Hua Liu, et al.
Published: (2020-02-01)

Effect of 21-gene recurrence score in decision-making for surgery in early stage breast cancer
by: Wu SG, et al.
Published: (2019-03-01)

The effects of trastuzumab on HER2-mediated cell signaling in CHO cells expressing human HER2
by: Hamid Maadi, et al.
Published: (2018-03-01)

Nuclear HER3 expression improves the prognostic stratification of patients with HER1 positive advanced laryngeal squamous cell carcinoma
by: Giovanni Almadori, et al.
Published: (2021-09-01)

Targeting EGFR/HER2/HER3 with a Three-in-One Aptamer-siRNA Chimera Confers Superior Activity against HER2+ Breast Cancer
by: Xiaolin Yu, et al.
Published: (2018-03-01)